Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
about
The 2007 WHO classification of tumours of the central nervous systemOligodendroglioma: pathology, molecular mechanisms and markersATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.Mass spectrometry imaging as a tool for surgical decision-making.Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspectiveMultidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.Receptor interactive protein kinase 3 promotes Cisplatin-triggered necrosis in apoptosis-resistant esophageal squamous cell carcinoma cells1p/19q testing has no significance in the workup of glioblastomas.Oligodendroglial neoplasms with ganglioglioma-like maturation: a diagnostic pitfall.Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistanceSurgical resection of malignant gliomas-role in optimizing patient outcome.An acidic environment changes cyclin D1 localization and alters colony forming ability in gliomas.Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas.L1 and CHL1 Cooperate in Thalamocortical Axon TargetingGene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy.Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation StatusPrognostic variables in oligodendroglial tumors: a single-institution study of 95 cases.The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.Inhibition of Pediatric Glioblastoma Tumor Growth by the Anti-Cancer Agent OKN-007 in Orthotopic Mouse Xenografts.How molecular testing can help (and hurt) in the workup of gliomas.Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.The evolving role of lenalidomide in the treatment of hematologic malignancies.Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome.1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomasPrimary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.Molecular neuropathology of gliomas.Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity.The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system.Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.Familial glioblastoma: A case report of glioblastoma in two brothers and review of literature.Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
P2860
Q24685772-85463D41-69A2-4514-90E4-ADDF3AA527EAQ27002448-9D2ED528-37DA-42A2-83A4-16EF56666034Q27852494-913CEACB-54DB-43AA-A883-D401E147B4C8Q33410196-C49BC9FB-AB59-4AD4-B79E-B9C9D7585D85Q33460052-8F43868E-8C8A-4904-ADA5-1C491A812E87Q33519196-1351D9BE-90F3-42C3-85F4-4EFCB73523B8Q33636469-A670503E-E43F-49D0-9557-E520BBDB3D6FQ33711322-9C80CA1E-AD72-454C-B0C7-CD08E81CA761Q33800218-B58318E1-250B-4DFE-9B27-A681D018FDADQ33893445-1676062D-2D09-49D3-8F14-2B94D38D7EC8Q33942865-2EB2ED86-35E1-43D2-A6DE-E79A027E0D94Q34062043-ACB338C8-742C-42CC-9B43-44EA5C505C6FQ34105339-709F17BB-FED5-40E1-8158-6A3A8846EC88Q34324963-5B14D244-3EF4-43C4-ADC9-41C4201AEE86Q34374920-B9058AAD-E085-416B-ADFA-677CB5E333BCQ34388126-58861EF2-184F-488E-849F-B01EF9A7AF8FQ34488140-4F6C753D-EB80-49EC-AA9C-EED93C6C9086Q34627868-989DA413-0F3A-4177-BC81-E30C033DFB6BQ34990522-11E828CB-0042-439B-9938-30C75658087CQ35028828-3EAA62B7-83A1-46BE-8164-A3A2E9A77D5DQ35419379-D57D125F-0FCB-4387-8CB1-037B7646AFFFQ35634042-7CF6597A-6A59-459A-A7E5-1AA18B8F0E2CQ35738941-6F6FA322-70C2-42F3-B505-8158DC191C85Q35770275-CAD16895-D229-4BD8-8871-C6FAC0C5C7BFQ36618241-7CBB3997-CF1B-46B8-957C-81BBA83A1CAAQ36739807-F3086E27-1173-4D77-B47A-A3BAFF1F2260Q36840568-C1B78EA6-7457-414A-B6AD-00B0A631CBA3Q36866053-14936E2A-B432-4746-AAFC-4928188AB04BQ36904087-E3975341-D4D6-4678-8BDC-7D76C4CB3869Q36955892-F3C119CD-84F0-4328-9480-2B7376E4B65FQ37151970-9F474590-D0FB-4FDF-88BF-EB25E019A13EQ37312716-9BEA719A-B4BE-4DBB-AFE5-E82B27C13677Q37427424-6EC25372-6021-4C85-AC05-BE4E6008D0DAQ37471678-3F1ED799-D07F-4330-B6C5-5B53C6E5B6BBQ37601178-8132AED4-6D40-41E0-89FB-8C2D1CA8E70EQ37715991-4455C9F7-F339-4039-A004-4173EF5C62A0Q37746324-0C812B02-A6EE-49B5-BDC6-06367156A00AQ37799825-9FA9BD4D-8405-41B6-B33B-298D0F15E98FQ37964672-291450A8-6E32-4436-8DE0-6D0A80302A73Q37976320-876AEBFA-7336-424F-BCEC-236264005DB6
P2860
Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Significance of necrosis in gr ...... diagnosed high-grade gliomas.
@en
Significance of necrosis in gr ...... diagnosed high-grade gliomas.
@nl
type
label
Significance of necrosis in gr ...... diagnosed high-grade gliomas.
@en
Significance of necrosis in gr ...... diagnosed high-grade gliomas.
@nl
prefLabel
Significance of necrosis in gr ...... diagnosed high-grade gliomas.
@en
Significance of necrosis in gr ...... diagnosed high-grade gliomas.
@nl
P356
P1476
Significance of necrosis in gr ...... y diagnosed high-grade gliomas
@en
P2093
Bernd W Scheithauer
Christopher P Dunham
P304
P356
10.1200/JCO.2006.08.1497
P407
P577
2006-12-01T00:00:00Z